Literature DB >> 11792566

Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.

E R Van Beek1, C W G M Löwik, S E Papapoulos.   

Abstract

Nitrogen-containing bisphosphonates (NBps) are taken up by osteoclasts and inhibit farnesyl pyrophosphate synthase, an enzyme of the mevalonate pathway. There is evidence, however, that cells other than mature osteoclasts, like osteoclast precursors and osteoblasts, are also involved in the action of Bps on bone resorption in vitro. To examine this issue further, we developed a new in vitro model, which allows the study of the effects of additives on early osteoclast precursors. In this model, osteogenic cells are essential for osteoclastogenesis. The model consists of 15-day-old fetal mouse metatarsals. At time of explantation, these bone rudiments do not yet contain a mineralized matrix or osteoclasts; only early osteoclast precursors are present in the perichondrium. During culture and after the addition of Nabeta-glycerolphosphate, the bones form a mineralized matrix that is consequently resorbed by osteoclasts that develop from their precursors. Short treatment of these explants with Bps, before the formation of a mineralized matrix, resulted in a subsequent dose-dependent inhibition of bone resorption. The relative potencies of eight Bps to suppress resorption were comparable with those observed after the addition of Bps after the formation of a mineralized matrix, the natural target of Bps. In addition, the effects of the NBp olpadronate, but not of clodronate, on osteoclastic resorption, could be partly reversed by geranylgeraniol. Results indicate that Bps can suppress osteoclastic resorption in vitro by a direct action on very early osteoclast precursors at the bone surface, and not by affecting the osteoclastogenic capacity of osteogenic cells. Moreover, the mechanism of action of the NBp olpadronate, but not clodronate, on early tartrate-resistant acid phosphatase-negative osteoclast precursors involves inhibition of protein geranylgeranylation, indicating a molecular mechanism similar to that established for mature osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11792566     DOI: 10.1016/s8756-3282(01)00655-x

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  38 in total

1.  Genetics of the bone response to bisphosphonate treatments.

Authors:  Francesco Massart; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

2.  Medication-related osteonecrosis of the jaw: a dentist's nightmare.

Authors:  Arvind Muthukrishnan; Laliytha Bijai Kumar; Gomathi Ramalingam
Journal:  BMJ Case Rep       Date:  2016-04-06

3.  Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts.

Authors:  Matthew Cozin; Bradley M Pinker; Kimberley Solemani; Jeremy M Zuniga; Stephen C Dadaian; Serge Cremers; Regina Landesberg; Srikala Raghavan
Journal:  J Oral Maxillofac Surg       Date:  2011-07-31       Impact factor: 1.895

4.  Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation.

Authors:  Nadine Hagelauer; Thomas Ziebart; Andreas M Pabst; Christian Walter
Journal:  Clin Oral Investig       Date:  2014-09-27       Impact factor: 3.573

5.  Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma.

Authors:  Victoria M Wu; Jarrett Mickens; Vuk Uskoković
Journal:  ACS Appl Mater Interfaces       Date:  2017-07-28       Impact factor: 9.229

6.  Osteoconductive action of alendronate after implantation of beta tricalcium phosphate in rat adjuvant-induced arthritis.

Authors:  Takahiro Netsu; Naoki Kondo; Katsumitsu Arai; Akira Ogose; Naoto Endo
Journal:  J Bone Miner Metab       Date:  2012-07-18       Impact factor: 2.626

7.  Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital.

Authors:  Zaid H Baqain; Faleh A Sawair; Zaid Tamimi; Nazzal Bsoul; Ghazi Al Edwan; Jamal K Almasad; Abdalla A Abbadi
Journal:  Ann R Coll Surg Engl       Date:  2010-06-01       Impact factor: 1.891

8.  Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats.

Authors:  Y F Li; E Luo; G Feng; S S Zhu; J H Li; J Hu
Journal:  Osteoporos Int       Date:  2009-12-03       Impact factor: 4.507

9.  Alendronate reduces osteoclast precursors in osteoporosis.

Authors:  P D'Amelio; A Grimaldi; M A Cristofaro; M Ravazzoli; P A Molinatti; G P Pescarmona; G C Isaia
Journal:  Osteoporos Int       Date:  2009-12-01       Impact factor: 4.507

10.  Osteonecrosis of the jaws caused by bisphosphonates: evaluation of a new therapeutic approach using the Er:YAG laser.

Authors:  Francesca Angiero; Carolina Sannino; Roberto Borloni; Rolando Crippa; Stefano Benedicenti; George E Romanos
Journal:  Lasers Med Sci       Date:  2009-03-11       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.